Swiss medical device maker Medacta H1 revenue rises on Asia Pacific, EMEA strength
Swiss medical device maker Medacta H1 revenue rises on Asia Pacific, EMEA strength
Overview
Switzerland medical device maker's H1 2026 revenue grew 9.7% in constant currency
Adjusted EBITDA margin for H1 2026 was 27.8% in constant currency
Net profit declined yr/yr due to one-off gain in prior year
Outlook
Medacta targets 2026 revenue growth of 10% to 14% in constant currency
Company expects 2026 adjusted EBITDA margin to expand by around 50bps vs prior year
Medacta sees 2024–2027E revenue CAGR of 12% to 15% in constant currency
Result Drivers
GEOGRAPHIC GROWTH MIX - Double-digit revenue growth in Asia Pacific and EMEA, with slower growth in North America due to US market softening and sales channel transition in Spine
PRODUCT INNOVATION - Growth in Hip, Knee, and Extremities segments attributed to new technologies such as AMIS platform, NextAR AR navigation, and GMK SpheriKA implants
NEW SURGEON ADOPTION - Increased revenues from new surgeon activities across all business lines, especially in US ambulatory surgery centers and academic centers
Company press release: ID:nEQ5Lj6X1a
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 Adjusted EBITDA |
| EUR 97 mln |
|
H1 Adjusted EBITDA Margin |
| 27.80% |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Medacta Group SA is CHF180.00, about 46.8% above its September 8 closing price of CHF122.60
The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 29 three months ago
Reuters Recommended Reads
Sept 8 - Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Medacta SA
See all newsBrief: Medacta Group Updates 2026 Guidance, Reiterates 2024-2027 Mid-Term Outlook
Swiss medical device maker Medacta H1 revenue rises on Asia Pacific, EMEA strength
Brief: Medacta H1 Adjusted EBITDA EUR 97 Million
Switzerland's Medacta H1 revenue rises 9.7% in constant currency
Brief: Medacta H1 Revenue EUR 368 Million